ANI also reported that Cadila Health’s ZyCoV-D has received restricted emergency use authorisation for children above the age of 12 years. Further, DCGI also granted emergency use authorisation to Corbevax for children between the age of 5-12 years, ANI reported citing sources.
ET on Friday had reported that the subject expert committee (
SEC) of the Drugs Controller General of
India (DCGI) on Friday recommended the use of
Bharat Biotech’s
Covaxin among children aged 6-12 years amid an uptick in cases in schools.
Covaxin, one of the main vaccines administered to adults, is currently being administered to children in the age group of 15-18 years.
Experts had sought additional data from the company which was presented on Friday.
#COVID19 | DCGI (Drugs Controller General of India) gives restricted emergency use authorisation to BharatBiotech’s… https://t.co/Ash49pLnob
— ANI (@ANI) 1650957246000
“The SEC was satisfied with the data and recommended its use among children aged 6-12 years,” a person aware of the matter said on condition of anonymity.
The focus has shifted to children’s vaccines amid a fresh surge in Covid-19 cases, especially among children. On Thursday, the SEC also recommended the use of Biological E’s Corbevax among children aged 5-12 years. Corbevax is currently being administered to children in the age group 12-14 years.
Vaccination for children aged 15-18 years started in January. In March, vaccination was extended to children above 12 years.
For all the latest world News Click Here
